M&A Deal Summary

Bio-Techne Acquires Asuragen

On March 3, 2021, Bio-Techne acquired medical products company Asuragen from Telegraph Hill Partners for 320M USD

Acquisition Highlights
  • This is Bio-Techne’s 3rd transaction in the Medical Products sector.
  • This is Bio-Techne’s largest (disclosed) transaction.
  • This is Bio-Techne’s 13th transaction in the United States.
  • This is Bio-Techne’s 1st transaction in Texas.

M&A Deal Summary
Date 2021-03-03
Target Asuragen
Sector Medical Products
Buyer(s) Bio-Techne
Sellers(s) Telegraph Hill Partners
Deal Type Add-on Acquisition
Deal Value 320M USD
Advisor(s) Perella Weinberg Partners (Financial)
Vinson & Elkins (Legal)

Target

Asuragen

Austin, Texas, United States
Asuragen, Inc. engages in the development, manufacturing, and commercialization of genetic carrier screening and oncology testing kits. Asuragen’s products leverage proprietary chemistries which can be used on widely available platforms including, PCR, qPCR, capillary electrophoresis, and next-generation sequencing instruments. Asuragen was established in 2006 and is based in Austin, Texas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bio-Techne

Minneapolis, Minnesota, United States
Category Company
Founded 1976
Sector Life Science
Employees3,200
Revenue 1.1B USD (2023)
DESCRIPTION
Bio-Techne's corporate headquarters in Minneapolis, Minnesota.
Bio-Techne's corporate headquarters in Minneapolis, Minnesota.

Bio-Techne is a life sciences company that provides bioactive tools and resources for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. Bio-Techne was founded in 1976 and is based in Minneapolis, Minnesota.

DEAL STATS #
Overall 15 of 18
Sector (Medical Products) 3 of 3
Type (Add-on Acquisition) 15 of 17
State (Texas) 1 of 1
Country (United States) 13 of 15
Year (2021) 2 of 2
Size (of disclosed) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-28 Changzhou Eminence Biotechnology

Changzhou, China

Changzhou Eminence Biotechnology Co., Ltd. focused on supplying life science companies with best-in-class media, including CHO cells (Chinese Hamster Ovary) and other serum-free media products, as well as custom cell-line and media formulation development services. Changzhou Eminence Biotechnology was founded in 2016 and is based in Changzhou, China.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-22 Namocell

Mountain View, California, United States

Namocell is a provider of fast and easy-to-use single-cell sorting and dispensing platforms that are gentle to cells, and preserve cell viability and integrity. Single cell selection and sorting is a critical technology in various workflows in both biotherapeutics and diagnostics, including cell and gene therapy development and commercialization, cell engineering, cell line development, single-cell genomics, antibody discovery, synthetic biology, and rare cell isolation. Namocell was formed in 2014 and is based in Mountain View, California.

Buy -

Seller(S) 1

SELLER

Telegraph Hill Partners

San Francisco, California, United States

Investor Investor Investor Investor Investor

Category Venture Capital Firm
Founded 2001
Size Middle-Market
Type Sector Focused
DESCRIPTION

Telegraph Hill Partners is a specialist private equity firm focused on investing in later-stage life science, medical device, and healthcare companies. Prospective companies should be at or near profitability and demonstrate success. Other areas of interest within the healthcare sector include life science technologies, chemistry/reagent suppliers, and information management. Telegraph Hill Partners was formed in 2001 and is based in San Francisco, California.

DEAL STATS #
Overall 21 of 28
Sector (Medical Products) 12 of 14
Type (Add-on Acquisition) 18 of 23
State (Texas) 3 of 3
Country (United States) 21 of 27
Year (2021) 1 of 5
Size (of disclosed) 2 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-19 Nivagen Pharmaceuticals

Sacramento, California, United States

Nivagen Pharmaceuticals is a specialty pharmaceutical company engaged in the development and sale of difficult to formulate generic and branded prescription drugs for the North American market. Nivagen was founded in 2009 and is based in Sacramento, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-15 Akoya Biosciences

Marlborough, Massachusetts, United States

Akoya Biosciences is a developer of technologies for life science researchers to enable spatially-resolved, quantitative tissue phenotyping at the cellular and subcellular level. The combined technologies of Phenoptics and CODEX are fueling advances in next-generation tissue analysis by providing comprehensive solutions including instrumentation, reagents, and software. Akoya Biosciences was founded in 2015 and is based in Marlborough, Massachusetts.

Sell -
Mergr

Product

Company

Legal